parathyroid disease: A disease involving the parathyroid gland.
Disorders of parathyroid gland, other and/or unspecified
DOID EFO Endpoint Browser PheWeb
E4_PARANAS
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
240 |
4. Check minimum number of eventsNone |
240 |
5. Include endpointsNone |
240 |
6. Filter based on genotype QC (FinnGen only) |
240 |
Control definitions (FinnGen only)
- Control exclude
- E4_ENDOGLAND
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Disorders of parathyroid gland, other and/or unspecified
based on the number of shared cases.
Similar with more cases:
- Disorders of parathyroid gland
- Disorders of other endocrine glands
- Endocrine, nutritional and metabolic diseases
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1856 | 1425 | 415 |
| Only index persons | 1503 | 1173 | 330 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.03 | 0.04 | 0.01 |
| Only index persons | 0.04 | 0.04 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 64.79 | 65.50 | 62.14 |
| Only index persons | 63.64 | 64.58 | 60.30 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 240 | 188 | 52 |
| Unadjusted period prevalence (%) | 0.06 | 0.06 | 0.02 |
| Median age at first event (years) | 60.18 | 60.32 | 59.69 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 227
- Matched controls
- 2278
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E21.5
ICD-10 Finland
Disorder of parathyroid gland, unspecified
+∞
187.3
153
*
E21.09
ICD-10 Finland
Other primary hyperparathyroidism
+∞
152.9
129
*
BBA30
NOMESCO Finland
Excision of lesion of parathyroid gland
768.0
61.8
58
*
BBA40
NOMESCO Finland
Subtotal parathyroidectomy
+∞
57.8
53
*
E21.3
ICD-10 Finland
Hyperparathyroidism, unspecified
351.6
55.8
54
*
E21.4
ICD-10 Finland
Other specified disorders of parathyroid gland
+∞
52.1
48
*
E21.0
ICD-10 Finland
Primary hyperparathyroidism
278.7
45.7
45
*
A11CC03
ATC
alfacalcidol; systemic
42.5
34.2
42
12
106
Kela drug reimbursment
Hypoparathyroidism
+∞
28.8
27
*
E83.50
ICD-10 Finland
Hypercalcemia
41.0
28.4
35
10
E21
ICD-10 Finland
Hyperparathyroidism and other disorders of parathyroid gland
+∞
27.7
26
*
A12AA04
ATC
calcium carbonate; oral
41.0
26.0
32
9
H05BX01
ATC
cinacalcet; oral
+∞
25.5
24
*
E21.2
ICD-10 Finland
Other hyperparathyroidism
279.4
25.2
25
*
321
Kela drug reimbursment
Paricalcitol and cinacalcet
218.2
19.9
20
*
A12AA06
ATC
calcium lactate gluconate; oral
+∞
19.0
18
*
NK6QA
NOMESCO Finland
Measurement of bone density from tow or more locations with X-ray
6.1
17.7
51
102
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
8.6
17.1
38
52
A11CC02
ATC
dihydrotachysterol; oral
+∞
15.8
15
*
BBA20
NOMESCO Finland
Exploration of parathyroid gland
159.8
14.6
15
*
N18.8
ICD-10 Finland
Other chronic renal failure
13.3
13.4
23
19
D35.1
ICD-10 Finland
Benign neoplasm: Parathyroid gland
+∞
12.6
12
*
E20.9
ICD-10 Finland
Hypoparathyroidism, unspecified
+∞
12.6
12
*
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
17.1
12.4
19
12
EP1AE
NOMESCO Finland
Neck ultrasound examination
6.2
11.9
32
58
E89.2
ICD-10 Finland
Postprocedural hypoparathyroidism
+∞
11.6
11
*
M14.1*E21.5
ICD-10 Finland
Crystal arthropathy in hyperparathyroidism
+∞
11.6
11
*
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
16.6
11.0
17
11
25298
ICD-8 Finland
Diseases of parathyroid gland, Alii definiti
+∞
10.5
10
*
E83.51
ICD-10 Finland
Hypocalcemia
34.3
10.4
13
*
127
Kela drug reimbursment
Transplant complication
24.7
10.4
14
6
M04AA01
ATC
allopurinol; systemic
3.7
10.2
46
144
205
Kela drug reimbursment
Chronic hypertension
2.5
9.5
98
523
Z94.0
ICD-10 Finland
Kidney transplant status
22.8
9.5
13
6
E34.9
ICD-10 Finland
Endocrine disorder, unspecified
+∞
9.4
9
*
D44.8
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Pluriglandular involvement
+∞
9.4
9
*
Z49.1
ICD-10 Finland
Extracorporeal dialysis
16.5
9.2
14
9
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.4
9.0
119
717
L04AA06
ATC
mycophenolic acid; systemic
17.1
8.7
13
8
KAS10
NOMESCO Finland
Allogenic transplantation of kidney from cadaver donor
28.7
8.6
11
*
E21.1
ICD-10 Finland
Secondary hyperparathyroidism, not elsewhere classified
93.4
8.5
9
*
196
Kela drug reimbursment
Paricalcitol and cinacalcet
93.4
8.5
9
*
E20.8
ICD-10 Finland
Other hypoparathyroidism
+∞
8.4
8
*
Q61.2
ICD-10 Finland
Polycystic kidney, autosomal dominant
+∞
8.4
8
*
C08CA13
ATC
lercanidipine; oral
3.0
8.3
51
200
WX408
NOMESCO Finland
General anesthesy, balanced
2.5
7.9
77
392
190
Kela drug reimbursment
Lanthanum carbonate, sevelamer and sucroferric oxyhydroxide
46.6
7.8
9
*
TK800
NOMESCO Finland
Hemodialysis
12.4
7.7
13
11
N18.0
ICD-10 Finland
End-stage renal disease
26.0
7.6
10
*
N18.5
ICD-10 Finland
Chronic kidney disease, stage 5
82.7
7.5
8
*
25299
ICD-8 Finland
Diseases of parathyroid gland, Other and unspecified
+∞
7.3
7
*
V03AE02
ATC
sevelamer; oral
+∞
7.3
7
*
E20.0
ICD-10 Finland
Idiopathic hypoparathyroidism
+∞
7.3
7
*
AA4CG
NOMESCO Finland
Extensive MRI examination of sella turcica with high intensity magnet
31.1
7.2
9
*
B03XA02
ATC
darbepoetin alfa; parenteral
12.6
7.2
12
10
C08CA01
ATC
amlodipine; oral
2.1
6.9
108
680
C03CA01
ATC
furosemide; systemic
2.2
6.9
95
564
UJF32
NOMESCO Finland
Coloscopy
2.3
6.8
78
427
WZC30
NOMESCO Finland
Teaching
2.8
6.8
45
182
PBL10
NOMESCO Finland
Construction of arteriovenous fistula from radial artery
23.3
6.7
9
*
M05BA04
ATC
alendronic acid; oral
2.9
6.7
41
158
M81.9
ICD-10 Finland
Osteoporosis, unspecified
4.2
6.6
24
62
I10
ICD-10 Finland
Essential (primary) hypertension
2.1
6.6
162
1218
BBA70
NOMESCO Finland
Implantation or transplantation of parathyroid gland
71.8
6.5
7
*
H02AB09
ATC
hydrocortisone; systemic
14.9
6.5
10
7
V03AE01
ATC
polystyrene sulfonate; oral
18.7
6.3
9
5
E26.0
ICD-10 Finland
Primary hyperaldosteronism
+∞
6.3
6
*
B05DA
ATC
Isotonic solutions
27.5
6.3
8
*
N19
ICD-10 Finland
Unspecified kidney failure
5.9
6.1
16
29
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.1
6.1
86
512
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
100
163
9.83
64.76
5.6
2.9
114.7
73.7
ng/l
2.43
85
139
94
238
5.86
37.53
10.0
4.8
1.1
1.1
mmol/l
0.37
87
213
187
1066
4.47
22.21
17.7
6.0
1.3
1.2
mmol/l
4.84
148
899
161
882
3.53
19.08
4.5
2.2
81.1
80.7
nmol/l
0.05
153
766
170
981
3.54
18.14
13.4
5.2
1.3
1.2
mmol/l
4.97
163
887
27
75
3.93
8.84
1.7
3.9
37.9
151.9
mg/l
0.71
16
59
27
75
3.93
8.84
1.7
3.9
32.0
26.0
mg/l
0.62
16
58
88
494
2.24
7.80
2.9
2.1
3.8
3.4
mg/l
0.36
78
421
59
282
2.45
7.55
5.3
2.2
19.3
21.3
%
0.67
53
234
17
37
4.87
7.53
2.2
2.3
4.4
4.9
e9/l
0.26
17
37
135
913
2.10
7.26
6.9
3.7
34.7
35.3
g/l
0.64
126
840
17
39
4.62
7.08
2.7
2.8
58.5
62.2
%
0.49
17
39
62
314
2.32
6.92
4.0
3.0
0.8
0.8
mmol/l
0.29
57
291
118
774
2.04
6.74
3.9
3.1
2.4
2.4
mmol/l
2.54
111
661
51
242
2.41
6.57
4.8
3.6
—
—
—
0
0
25
81
3.33
6.53
1.8
1.8
11.2
4.8
ug/l
0.27
20
73
156
1147
2.04
6.30
7.5
9.4
4.4
4.1
e9/l
1.16
141
1003
120
806
1.98
6.28
4.6
2.5
194.8
120.7
ug/l
1.61
110
726
17
45
3.99
5.92
6.8
2.1
15.0
15.4
%
—
10
19
84
516
1.97
5.54
4.0
2.6
6367.7
11593.7
umol/l
0.36
73
427
33
141
2.56
5.28
1.8
1.6
—
—
—
0
0
16
47
3.58
4.84
8.3
2.6
8.3
7.7
kpa
0.78
16
41
72
440
1.91
4.72
2.1
1.7
1306.8
1249.3
nmol/l
0.17
53
315
57
322
2.01
4.69
1.7
1.8
—
—
—
0
0
52
285
2.05
4.64
20.8
23.7
1.6
1.3
inr
—
9
41
12
32
3.90
4.14
2.6
1.8
89.4
90.0
%
0.12
12
32
117
855
1.72
4.11
5.2
3.9
28.7
31.4
ng/l
0.19
98
635
107
764
1.73
4.08
5.5
3.1
—
—
—
0
0
189
1590
1.90
3.99
10.4
7.2
82.1
79.6
u/l
0.33
184
1467
72
465
1.78
3.87
1.7
1.8
721.1
478.7
pmol/l
0.50
60
368
7
8
8.97
3.80
3.6
6.3
—
—
—
0
0
87
601
1.70
3.66
4.6
3.0
0.1
0.5
e6/l
3.23
69
434
94
673
1.65
3.41
2.3
2.0
103.8
200.6
u/l
2.47
89
622
56
356
1.75
3.12
1.4
1.3
19.8
46.1
iu/ml
2.58
24
119
22
100
2.32
3.10
4.3
3.3
25.2
24.6
mmol/l
0.27
15
90
20
88
2.39
3.03
1.4
1.8
—
—
—
0
0
36
201
1.93
3.02
4.7
3.2
1.4
2.6
mmol/l
0.83
28
159
165
1381
1.63
3.02
6.4
5.0
—
4516.1
—
0
29
131
1044
1.56
2.91
6.0
4.2
0.0
0.0
estimate
0.00
42
208
180
1549
1.66
2.85
6.4
4.1
15.8
15.1
pmol/l
3.09
165
1375
106
814
1.54
2.73
6.6
4.4
—
—
—
0
0
131
1056
1.53
2.68
7.3
5.6
0.0
0.0
estimate
0.00
41
202
87
643
1.56
2.64
2.8
2.3
58.4
57.0
u/l
0.09
81
583
176
1519
1.60
2.62
6.1
4.3
15.9
13.6
mm/h
1.10
168
1365
8
20
4.10
2.59
1.3
1.4
—
—
—
0
0
91
682
1.54
2.59
3.5
3.0
1622.8
1476.8
ng/l
0.14
79
578
12
44
2.82
2.58
1.5
1.2
—
—
—
0
0
131
1062
1.52
2.57
6.1
4.2
0.0
0.0
estimate
0.50
40
199
35
205
1.83
2.55
4.8
3.2
5.6
5.8
kpa
0.57
35
200
204
1833
1.77
2.53
7.2
5.1
1.9
2.0
mu/l
0.14
190
1640
81
595
1.55
2.51
7.2
4.5
0.0
0.0
estimate
0.00
41
199
123
991
1.50
2.45
2.4
2.6
—
—
—
0
0
8
23
3.56
2.29
1.1
1.3
—
—
—
0
0
8
23
3.56
2.29
1.3
1.3
—
—
—
0
0
6
13
4.70
2.28
1.7
1.2
—
—
—
0
0
7
18
3.97
2.27
1.1
1.1
—
—
—
0
0
64
456
1.55
2.24
1.8
1.6
2.4
1.1
mg/l
0.44
43
368
5
9
5.65
2.22
1.0
1.4
4.8
9.6
u/l
—
5
9
6
14
4.37
2.16
1.0
1.1
—
—
—
0
0
8
25
3.27
2.11
2.6
1.4
—
—
—
0
0
63
454
1.53
2.09
3.0
2.8
2.6
2.5
mmol/l
1.82
58
399
37
235
1.68
2.06
1.6
1.7
—
—
—
0
0
109
879
1.44
2.05
2.2
2.0
105.4
100.0
pmol/l
0.35
50
398
37
236
1.67
2.03
1.6
1.7
—
—
—
0
0
9
33
2.79
1.95
1.3
1.3
—
—
—
0
0
5
11
4.62
1.95
1.6
2.4
3797.2
1020.5
u/ml
—
5
11
13
58
2.31
1.94
1.2
1.5
—
—
—
0
0
70
526
1.47
1.88
1.6
1.5
20.8
22.7
nmol/l
0.42
64
430
8
29
2.82
1.81
1.3
1.4
—
—
—
0
0
14
67
2.16
1.80
1.1
1.2
—
—
—
0
0
20
111
1.88
1.75
5.3
3.3
53.4
48.1
%
0.33
20
111
5
13
3.90
1.72
5.2
4.9
—
51.0
u/ml
—
0
5
7
25
2.85
1.66
1.9
1.4
21.4
16.8
ug/l
—
7
25
7
25
2.85
1.66
2.0
1.2
—
—
nmol/l
—
0
0
22
129
1.78
1.63
1.9
1.2
—
—
—
0
0
14
70
2.06
1.63
1.2
1.8
36.3
36.9
g/l
0.13
14
63
55
406
1.46
1.61
4.4
3.7
53.3
141.9
ng/l
1.08
49
340
27
170
1.66
1.57
5.5
3.1
40.6
57.6
ml/min/173m2
1.39
16
66
28
179
1.64
1.54
4.6
2.4
5.1
4.3
kpa
0.76
28
173
6
21
2.90
1.51
1.3
1.0
—
—
—
0
0
19
110
1.79
1.48
4.4
3.0
22.7
25.1
mmol/l
1.16
19
110
12
59
2.09
1.46
1.8
2.4
—
—
—
0
0
16
89
1.85
1.41
1.0
1.0
—
—
—
0
0
127
1100
1.33
1.38
6.1
5.8
9.5
10.5
umol/l
1.23
122
1031
6
23
2.65
1.37
1.0
1.5
—
—
—
0
0
6
23
2.65
1.37
1.0
1.1
—
—
—
0
0
5
17
2.98
1.36
3.6
2.5
—
—
—
0
0
210
1974
1.53
1.32
25.1
14.8
20.4
22.6
mg/l
0.61
184
1573
46
341
1.43
1.32
1.4
1.3
1.3
13.6
u/ml
2.71
16
123
9
43
2.13
1.32
1.2
1.5
—
—
—
0
0
8
34
2.40
1.30
1.3
1.6
—
—
—
0
0
201
1876
1.45
1.29
7.7
6.0
41.7
40.1
mmol/mol
1.26
185
1721
6
25
2.43
1.25
1.0
1.6
—
—
—
0
0
11
56
2.01
1.24
1.6
1.3
—
8.5
—
0
14
8
38
2.14
1.19
1.6
1.5
—
—
—
0
0
57
447
1.36
1.18
2.8
2.2
—
—
—
0
0
12
65
1.89
1.15
1.9
1.8
—
—
—
0
0
47
361
1.38
1.11
2.9
2.6
1.6
0.9
e6/l
0.43
28
194
8
41
1.98
1.10
1.3
1.3
—
—
—
0
0
11
59
1.91
1.09
1.6
1.3
—
1.2
—
0
5
5
22
2.30
1.04
1.0
1.5
—
—
—
0
0
103
896
1.26
0.99
5.1
3.9
—
—
—
0
0
5
23
2.20
0.98
1.0
1.1
—
—
—
0
0
17
109
1.60
0.96
1.2
1.2
106.6
202.7
u/ml
0.81
17
97
215
2058
1.45
0.92
29.3
18.1
106.0
75.3
umol/l
4.46
215
2058
6
28
2.17
0.92
1.0
1.5
—
—
—
0
0
43
338
1.33
0.89
3.4
2.8
5.7
3.0
e6/l
0.57
25
174
12
72
1.70
0.87
2.1
1.9
—
—
—
0
0
8
46
1.76
0.83
1.3
1.5
—
—
—
0
0
27
199
1.40
0.83
3.7
2.1
5.9
8.1
umol/l
0.49
22
168
11
66
1.70
0.80
2.1
1.6
—
—
—
0
0
24
175
1.41
0.78
3.5
2.5
409.1
222.8
ng/l
0.61
24
160
33
255
1.34
0.77
6.4
5.8
104.2
104.0
mmol/l
0.08
33
250
11
67
1.67
0.76
2.1
1.8
—
—
—
0
0
195
1854
1.28
0.75
24.8
14.6
64.4
75.4
ml/min/173m2
7.47
186
1508
9
55
1.66
0.74
2.1
1.5
—
—
—
0
0
19
261
0.70
0.72
7.5
7.7
—
—
—
0
0
17
118
1.47
0.71
3.9
2.2
0.9
1.1
%
0.91
17
118
7
41
1.73
0.70
1.3
1.3
—
—
—
0
0
0
21
0.00
0.60
0.0
1.0
—
—
—
0
0
7
113
0.61
0.59
2.3
1.8
—
—
—
0
0
0
22
0.00
0.59
0.0
1.0
—
—
—
0
0
6
36
1.68
0.57
1.8
1.1
32.7
15.0
u/l
—
6
31
7
46
1.54
0.48
1.0
1.3
—
—
—
0
0
185
1915
0.85
0.44
5.2
4.7
1.5
1.6
mmol/l
1.27
165
1733
47
409
1.19
0.44
1.3
1.2
2.5
1.4
u/ml
0.26
15
105
0
15
0.00
0.41
0.0
1.9
—
—
—
0
0
0
15
0.00
0.41
0.0
2.2
—
—
—
0
0
0
16
0.00
0.41
0.0
1.1
—
1.0
—
0
11
0
16
0.00
0.41
0.0
1.9
—
—
—
0
0
0
16
0.00
0.41
0.0
1.0
—
—
—
0
0
0
18
0.00
0.40
0.0
1.2
—
—
—
0
0
187
1927
0.86
0.37
5.2
4.7
4.6
4.7
mmol/l
1.03
168
1753
213
2083
1.21
0.36
14.3
10.9
24.2
23.6
u/l
0.23
206
1991
6
43
1.41
0.35
1.0
1.2
388.3
207.9
e6/l
—
6
35
6
43
1.41
0.35
1.0
1.1
39.0
5.4
e6/l
—
6
34
23
192
1.22
0.33
5.7
5.9
1.4
1.3
mmol/l
0.05
23
182
199
1944
1.14
0.28
5.5
4.9
6.1
6.0
mmol/l
0.85
175
1747
10
76
1.33
0.28
2.6
1.6
—
—
—
0
0
15
122
1.24
0.27
1.7
1.6
—
—
—
0
0
8
65
1.24
0.27
1.4
1.7
—
—
—
0
0
6
82
0.72
0.24
1.5
1.1
—
—
—
0
0
6
82
0.72
0.24
1.5
1.1
—
—
—
0
0
27
238
1.15
0.23
6.9
6.7
5.0
5.1
kpa
0.18
27
226
27
238
1.15
0.23
6.9
6.7
10.2
11.9
kpa
1.88
27
226
5
41
1.22
0.22
1.4
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.6
—
—
—
0
0
0
11
0.00
0.21
0.0
1.6
—
—
—
0
0
0
11
0.00
0.21
0.0
1.6
—
—
—
0
0
0
11
0.00
0.21
0.0
1.6
—
—
—
0
0
0
11
0.00
0.21
0.0
2.6
—
13.6
—
0
11
0
10
0.00
0.21
0.0
4.0
—
—
—
0
0
0
10
0.00
0.21
0.0
4.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
5
43
1.17
0.21
1.0
1.1
3.9
3.9
mmol/l
—
5
37
10
80
1.26
0.21
2.7
1.8
—
—
—
0
0
24
268
0.88
0.18
5.2
4.4
25.4
21.8
%
0.52
14
136
36
330
1.11
0.18
5.9
5.2
2.6
3.2
ug/l
0.21
28
290
182
1851
0.93
0.15
4.7
4.2
1.4
1.3
mmol/l
2.18
162
1669
45
474
0.94
0.11
7.8
4.5
1.0
1.0
kg/l
2.00
11
66
5
45
1.11
0.10
1.0
1.4
—
—
—
0
0
5
45
1.11
0.10
1.0
1.4
—
—
—
0
0
24
258
0.92
0.10
1.4
1.5
—
—
—
0
0
24
258
0.92
0.10
4.9
4.7
36.2
33.8
%
0.39
17
163
28
298
0.93
0.09
1.4
1.4
—
—
—
0
0
6
58
1.04
0.08
1.7
1.3
—
—
—
0
0
121
1187
1.04
0.08
4.1
2.9
65.6
47.6
u/l
0.98
111
1090
58
566
1.03
0.04
1.6
1.6
1.5
1.3
mmol/l
0.82
41
455
199
1980
1.03
0.03
5.7
5.4
2.6
2.7
mmol/l
1.04
178
1784
18
187
0.96
0.01
2.9
2.4
2.5
4.8
ug/l
3.39
18
164
19
191
0.99
0.00
8.9
7.4
119.0
119.6
g/l
0.04
19
185
169
1688
1.00
0.00
20.7
16.2
38.2
38.9
%
0.32
96
1133
11
113
0.97
0.00
1.3
1.2
151.1
138.1
iu/ml
—
6
49
0
8
0.00
0.00
0.0
1.8
—
—
—
0
0
0
8
0.00
0.00
0.0
1.8
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
10
100
1.00
0.00
1.3
1.3
—
—
—
0
0
0
9
0.00
0.00
0.0
1.7
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
2.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint E4_PARANAS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_PARANAS | 1.495 [1.3, 1.72] | < 0.001 |
| Birth year | 0.993 [0.98, 1.0] | 0.123 |
During the follow-up period (1.1.1998 — 31.12.2019), 411 out of 1112 females with E4_PARANAS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_PARANAS | 1.696 [1.3, 2.22] | < 0.001 |
| Birth year | 0.985 [0.98, 1.0] | 0.003 |
During the follow-up period (1.1.1998 — 31.12.2019), 129 out of 310 males with E4_PARANAS died.
Mortality risk
Mortality risk for people of age
years, who have E4_PARANAS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.142% | 0.283% |
| 5 | 0.791% | 1.52% |
| 10 | 2.046% | 4.214% |
| 15 | 4.067% | 8.631% |
| 20 | 7.273% | 14.569% |
Relationships between endpoints
↥Index endpoint: E4_PARANAS – Disorders of parathyroid gland, other and/or unspecified
GWS hits: 2
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data